Regeneron Pharmaceuticals, Inc. (REGN) Sees Bump In Call Activity

Regeneron Pharmaceuticals Inc's (REGN) calls are crossing at five times the normal rate

by Digital Content Group

Published on Feb 19, 2015 at 1:34 PM
Updated on Jun 24, 2020 at 10:16 AM

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is up 4.6% today at $424.31, after its drug for vision loss, Eylea, outperformed competitors in a study. As a result, calls are trading at five times normal levels in REGN's options pits, with speculators eyeing the February 425 call. Data shows buy-to-open activity here, as traders look for the equity to rally above $425 by tomorrow's close, when the contracts expire. REGN has already reached an intraday high of $428.47.

This bullish betting echoes the recent trend in the stock's options pits, as call buying has been hot the past two weeks. REGN's 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) call/put volume ratio of 1.44 is higher than 80% of similar readings from the past year.

The shares of REGN have been a favorite of short sellers, however, so some of this recent call buying could be bearish traders seeking out a hedge. Specifically, 4.6 million shares of REGN are sold short, representing over a week's worth of trading, at normal daily volumes.

Today's gains put Regeneron Pharmaceuticals Inc (NASDAQ:REGN) back in the black on a year-to-date basis -- 3.4% higher, to be exact. The shares could now be seeing a lift from their 20-week moving average, which has acted as support in the past.

Weekly Chart of REGN Since June 2014 With 20-Week Moving Average

A Schaeffer's 39th Anniversary Exclusive!

8 Top Stock Picks for 2020

Access your FREE insider report before it's too late!


  
 
 

Partnercenter